Johnson & Johnson
JNJ
Company Profile
Business description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Contact
One Johnson & Johnson Plaza
New BrunswickNJ08933
USAT: +1 732 524-0400
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
140,800
Johnson & Johnson News & Analysis
markets
US stock market outlook: Where to find value after April’s rally
Our reallocation strategy is working as intended. Opportunities remain in AI, tech, and small-caps.
personal-finance
Howard Marks warns of stock market froth
The renowned investor has penned his first investor letter for 2025 and it’s a ripper. He runs through what bubbles are, which ones he’s experienced, and whether today’s markets qualify as the third major bubble of this century.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,272.00 | 10.00 | -0.11% |
| CAC 40 | 8,636.80 | 13.76 | -0.16% |
| DAX 40 | 26,440.31 | 140.57 | 0.53% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,750.11 | 22.56 | -0.21% |
| HKSE | 25,521.99 | 405.14 | 1.61% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 68,895.98 | 182.18 | 0.27% |
| NZX 50 Index | 13,782.81 | 71.57 | -0.52% |
| S&P 500 | 7,785.76 | 13.23 | -0.17% |
| S&P/ASX 200 | 9,068.30 | 11.00 | -0.12% |
| SSE Composite Index | 3,960.19 | 33.01 | 0.84% |